| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Minireview |
Department of Medicine [M. A. S., G. K. S.], Division of Solid Tumor Oncology [G. K. S.], and Laboratory of Gastrointestinal Oncology and New Drug Development [M. A. S., G. K. S.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021
The concept of combining chemotherapeutic agents to increase cytotoxic efficacy has evolved greatly over the past several years. The rationale for combination chemotherapy has centered, in the past, on attacking different biochemical targets, overcoming drug resistance in heterogeneous tumors, and by taking advantage of tumor growth kinetics with increasing the dose-density of combination chemotherapy. The overall goal was to improve clinical efficacy with acceptable clinical toxicity. With our increased understanding of the cell cycle and the impact chemotherapeutic agents have on the cell cycle, it is increasingly apparent that this physiology can create drug resistance, thereby reducing combination chemotherapeutic efficacy. This is particularly relevant with the advent of cell cycle-specific inhibitors but also has relevance for the action of standard chemotherapeutic agents currently in clinical practice. This cell cycle-mediated resistance may be overcome by a greater understanding of chemotherapeutic cell cycle effects and by appropriate sequencing and scheduling of agents in combination chemotherapy. In this review, we have elected to illustrate the evolving concept of cell cycle-mediated drug resistance with novel drug combinations that include the taxanes, camptothecins, and fluorouracil. This review indicates that as our understanding of the cell cycle grows, our ability to appropriately sequence chemotherapy to overcome cell cycle-mediated drug resistance can have a great impact on our therapeutic approach in the treatment of human cancers.
This article has been cited by other articles:
|
|
 |
|
  L. Wang, G.-B. Zhou, P. Liu, J.-H. Song, Y. Liang, X.-J. Yan, F. Xu, B.-S. Wang, J.-H. Mao, Z.-X. Shen, et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia PNAS, March 25, 2008; 105(12): 4826 - 4831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Aneja, A. M. Ghaleb, J. Zhou, V. W. Yang, and H. C. Joshi p53 and p21 Determine the Sensitivity of Noscapine-Induced Apoptosis in Colon Cancer Cells Cancer Res., April 15, 2007; 67(8): 3862 - 3870. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Fischer, S. Muller-Weeks, and S. J. Caradonna Fluorodeoxyuridine Modulates Cellular Expression of the DNA Base Excision Repair Enzyme Uracil-DNA Glycosylase. Cancer Res., September 1, 2006; 66(17): 8829 - 8837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Petty, K. M. Kerr, G. I. Murray, M. C. Nicolson, P. H. Rooney, D. Bissett, and E. S.R. Collie-Duguid Tumor Transcriptome Reveals the Predictive and Prognostic Impact of Lysosomal Protease Inhibitors in Non-Small-Cell Lung Cancer J. Clin. Oncol., April 10, 2006; 24(11): 1729 - 1744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Schwartz and M. A. Shah Targeting the Cell Cycle: A New Approach to Cancer Therapy J. Clin. Oncol., December 20, 2005; 23(36): 9408 - 9421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Fujie, H. Yamamoto, C. Y. Ngan, A. Takagi, T. Hayashi, R. Suzuki, K. Ezumi, I. Takemasa, M. Ikeda, M. Sekimoto, et al. Oxaliplatin, a Potent Inhibitor of Survivin, Enhances Paclitaxel-induced Apoptosis and Mitotic Catastrophe in Colon Cancer Cells Jpn. J. Clin. Oncol., August 1, 2005; 35(8): 453 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Shah, J. Kortmansky, M. Motwani, M. Drobnjak, M. Gonen, S. Yi, A. Weyerbacher, C. Cordon-Cardo, R. Lefkowitz, B. Brenner, et al. A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol Clin. Cancer Res., May 15, 2005; 11(10): 3836 - 3845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Fishel, D. R. Newell, R. J. Griffin, R. Davison, L.-Z. Wang, N. J. Curtin, E. G. Zuhowski, K. Kasza, M. J. Egorin, R. C. Moschel, et al. Effect of Cell Cycle Inhibition on Cisplatin-Induced Cytotoxicity J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 206 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Waldman Markers of Cell Cycle-Mediated Drug Resistance And Prognosis Of Patients Receiving Preoperative Combined Modality Therapy For Rectal Cancer Ann. Surg. Oncol., November 1, 2004; 11(11): 949 - 950. [Full Text] [PDF]
|
|
|
|
|
|
H. G. Moore, J. Shia, D. S. Klimstra, L. Ruo, M. Mazumdar, G. K. Schwartz, B. D. Minsky, L. Saltz, and J. G. Guillem Expression of p27 in Residual Rectal Cancer after Preoperative Chemoradiation Predicts Long-term Outcome Ann. Surg. Oncol., November 1, 2004; 11(11): 955 - 961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Ozvaran, X. X. Cao, S. D. Miller, B. A. Monia, W. K. Hong, and W. R. Smythe Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma Mol. Cancer Ther., May 1, 2004; 3(5): 545 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. Gardner and M. Fernandes New tools for cancer chemotherapy: computational assistance for tailoring treatments Mol. Cancer Ther., October 1, 2003; 2(10): 1079 - 1084. [Abstract] [Full Text]
|
|
|
|
|
|
B. Yu, S. Kusmartsev, F. Cheng, M. Paolini, Y. Nefedova, E. Sotomayor, and D. Gabrilovich Effective Combination of Chemotherapy and Dendritic Cell Administration for the Treatment of Advanced-Stage Experimental Breast Cancer Clin. Cancer Res., January 1, 2003; 9(1): 285 - 294. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
